Prophylaxis in Haemophilia: A Double‐blind Controlled Trial

Publisher Website
Google Scholar
Abstract
A double-blind controlled trial of prophylactic factor VIII therapy was carried out on 9 severe hemophiliacs at the Lord Mayor Treloar College. Infusions were given once weekly and calculated to give a post-infusion plasma concentration of at least 0.25 I.U./ml of factor VIII. This regime reduced the overall bleeding frequency by 15%. The bleeding frequency in the first 3 days post-infusion was reduced by 66%. A moderate overall reduction in morbidity was also achieved. To reduce the incidence of bleeding in severe hemophiliacs by 15%, would probably require a 73% increased usage of therapeutic materials. More than twice this amount of material is likely to be needed to reduce the bleeding frequency of the same group by 66%.